TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02211989
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01070810
Drug: Thiamine
Normalized name: Thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiamine 200mg in 50ml D5W
Study: NCT05002101
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children with weight more than 10 kg were asked to take 5 ml syrup daily, while children with weight less than 10 kg were asked to take 2.5 ml daily.
Study: NCT01132079
Drug: cream treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01182077
Drug: ASP015K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01813019
Drug: AFQ056
Approvals — FDA: no, EMA: no, PMDA: no
Description: mGluR5 antagonist
Study: NCT01813019
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT01543269
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of Placebo in fasting condition with 240±10 ml of water at sitting position in ambient temperature.
Study: NCT03352115
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 day course of oral prednisolone
Study: NCT03352115
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo syrup
Study: NCT05090449
Drug: Chlorthalidone (HIGROTON® 50)
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets with 50mg of Chlorthalidone, product de Sandoz, S.A. de C.V.
Study: NCT05090449
Drug: A1+ A2 Co-administration of Chlorthalidone and Losartan
Normalized name: Atenolol and Chlorthalidone Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg chlorthalidone + 100 mg losartan potassium
Study: NCT05090449
Drug: Chlorthalidone + Losartan Fixed-Dose combination
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets with fixed combination of Chlorthalidone 25 mg and Losartan Potassium
Study: NCT03965052
Drug: Travatan 0.004 % Ophthalmic Solution
Normalized name: Travatan 0.004 % Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Generic name: Travoprost~* Distinctive denomination: Travatan®~* Active ingredients: Travoprost 0.004%~* Pharmaceutical form: Ophthalmic solution.~* Presentation: multi-dose dropper bottle, 2.5 milliliters.~* Prepared by: Alcon Laboratories Inc.~* Description of the solution: transparent solution, free of visible particles.~* Consult information to prescribe.
Study: NCT00761059
Drug: Glucose 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: The oral application of 0,3 ml/kg Glucose 20% 3 minutes before nasopharyngeal suctioning
Study: NCT03970109
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet
Study: NCT02322697
Drug: Intravenous administration of L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic intravenous administration of L-carnitine (1000mg on each dialysis session) for 1 year in hemodialysis patients
Study: NCT01313572
Drug: Adenosine SPECT-MPI
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute
Study: NCT03221257
Drug: Placebo (Plac)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a Plac, matched to resemble PFD, titrated up to a target dose of 801 mg taken three times daily as tolerated (3-step titration occurring at 2 week intervals).
Study: NCT03519230
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60mg BID, PO
Study: NCT04208412
Drug: KVD900
Approvals — FDA: no, EMA: no, PMDA: no
Description: KVD900 tablet 600 mg
Study: NCT01347203
Drug: DPOC-4088
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation A = 16 hr release formulation)
Study: NCT01347203
Drug: DPOC-4088
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation A = 16 hr release formulation)
Study: NCT01347203
Drug: DPOC-4088
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation B = 20 hr release formulation)
Study: NCT01347203
Drug: DPOC-4088
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation B = 20 hr release formulation)
Study: NCT01196728
Drug: CM3.1-AC100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD study with single ascending subcutaneous doses
Study: NCT04666441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV or SC single dose to match
Study: NCT00298038
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01823393
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valvuloplasty is performed in a conventional manner, ie with an injection of unfractionated heparin (50 IU / kg) at the start of procedure
Study: NCT00389818
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2 IV Day 1 of each cycle
Study: NCT00389818
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/m2 IV Day 1 of each cycle
Study: NCT02710526
Drug: CAM2038
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-Acting Subcutaneous Injectable Depot of Buprenorphine
Study: NCT00499369
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00499369
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01626976
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution, single dose
Study: NCT01626976
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: suspension, single dose
Study: NCT03952039
Drug: Best Available Therapy (BAT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best available therapy (BAT)
Study: NCT01818336
Drug: Penicillin skin test kit
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergy skin testing is done by puncture and intradermal. If all tests negative, subjects receive an oral amoxicillin challenge.
Study: NCT02305940
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An oral dose of 100 mg of Doxycycline once daily, for a total duration of 52 weeks.
Study: NCT02305940
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An oral dose of one capsule of placebo once daily, for a total duration of 52 weeks
Study: NCT03258476
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule
Study: NCT03195413
Drug: 1:1 volume measured solution of: 1% lidocaine without epinephrine and 0.5% bupivacaine without epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is the anesthetic solution that will be administered during the ultrasound-guided nerve block
Study: NCT01055392
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo tablets were administered twice-a-day for two years.
Study: NCT05038059
Drug: ethanolic extract of sapindus mukorossi
Normalized name: Sapindus mukorossi whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: ethanolic extract will be used as final endodontic irrigant during root canal procedures in extracted teeth.
Study: NCT05038059
Drug: ethylene diamine tetra acetic acid
Normalized name: Ethylene-diamine
DrugBank: Ethylenediamine (DB14189)
Approvals — FDA: no, EMA: no, PMDA: no
Description: used as final endodontic irrigant in root canal therapy
Study: NCT04011475
Drug: Other LABA/LAMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiotropium/olodaterol, indacaterol/glycopyrronium, vilanterol/umeclidinium
Study: NCT00760279
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02329405
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00126048
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT02192684
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compare with pioglitazone
Study: NCT01607905
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 500 mg (in Cycle 1, Week 1) to 1000 mg (in Cycle 1, Week 2 and onwards) of acetaminophen will be administered 1 hour prior to each selinexor dose up to 8 doses per cycle (28 days per cycle)
Study: NCT00000435
Drug: None-placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo was taken in pill form at 25mg/day for 6 months
Study: NCT01917045
Drug: Sufentanil (R30730, brand name Sufenta)
Normalized name: sufentanil Injection [Sufenta]
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sufentanil 1ug/ml
Study: NCT02284828
Drug: BIA 2-093
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01428492
Drug: GSK2110183
Approvals — FDA: no, EMA: no, PMDA: no
Description: The oral, once daily dose of GSK2110183 will be dependent on the cohort to which a subject is assigned. Subjects enrolled in Cohort 1 will receive 75 mg GSK2110183 once daily. Dose escalation in Schedule A and Schedule B will follow 25 mg increments in a 3+3 dose escalation procedure up to a maximum of 150mg daily or until MTD is reached, whichever comes first, for each schedule. GSK2110183 will continue at daily dosing until treatment discontinuation criteria is met.
Study: NCT03773744
Drug: Ad-MAGEA3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenovirus vaccine expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen
Study: NCT03773744
Drug: MG1-MAGEA3
Approvals — FDA: no, EMA: no, PMDA: no
Description: MG1 Maraba oncolytic virus expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen
Study: NCT03773744
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low-dose chemotherapy
Study: NCT02193620
Drug: Placebo soft capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose of oral Placebo soft capsules, initial dose: 2 capsules, then 1 capsule; t.i.d.
Study: NCT02193620
Drug: Dicofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive diclofenac by IM injection for analgesia as rescue pain control.
Study: NCT02991209
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02991209
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03708341
Drug: Melatonin 5 mg
Normalized name: melatonin 5 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Systematic daily administration of melatonin 5 mg during patient's ICU stay
Study: NCT03708341
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic daily administration of placebo during patient's ICU stay
Study: NCT02647151
Drug: METHYLAMINOLEVULINATE HYDROCHLORIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an intrapatient randomized clinical trial. All patients participating in the trial will receive both, experimental and control treatment, randomization will be used to determine side (right or left for treatment). Three visits will be scheduled. In the first visit epidemiological data will be collected , Actinic Keratoses are counted and drawn in a transparent template and also a photograph of each side. In that first visit treatment the PDT will be also performed, the degree of fluorescence, the pain and the degree of immediate local reaction will be measured.~skin after PDT. In the second visit, to be held at 2 or 3 days, the delayed local reaction degree will be assessed. And in the third visit, held a month of PDT the clinical response and patient satisfaction will be assessed.
Study: NCT02106338
Drug: CRS3123
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRS3123, a methionyl-tRNA synthetase inhibitor, formulated in 100 and 200 mg capsules; 8 subjects randomized in Cohorts A through C receive doses of 200 mg, 400 mg; and 600 mg or 100mg are planned respectively given orally every 12 hours for 10 days.
Study: NCT04498884
Drug: Rinsulin® mix 30/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: one subcutaneous injection at a dose of 0.4 IU/kg
Study: NCT04498884
Drug: Humulin® M3
Approvals — FDA: no, EMA: no, PMDA: no
Description: one subcutaneous injection at a dose of 0.4 IU/kg
Study: NCT00094380
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00226941
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is a cancer medication, and is administered based on m² of body surface area (BSA) delivered in equivalent morning and evening doses
Study: NCT00928317
Drug: ART621
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0mg/kg s.c.
Study: NCT00928317
Drug: ART621
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5mg/kg s.c.
Study: NCT00928317
Drug: ART621
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75mg/kg s.c.
Study: NCT00928317
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo s.c.
Study: NCT02966080
Drug: HEP-IV
Normalized name: heparin sodium, porcine Injectable Solution [Hep-Pak]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04840095
Drug: Ketones
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sports supplement that is administered mid-scan.
Study: NCT00002526
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00486343
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets 2x600mg BID for 24 weeks
Study: NCT00659269
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are treated per standard of care according to the choice of the treating physician with heavy metals (cisplatin, oxaliplatin), taxanes (paclitaxel, docetaxel), or vinca alkaloids (vincristine, vinorelbine)~Ranges of cumulative doses (in mg/m2) are:~paclitaxel, 700-960; docetaxel, 240-400; vincristine, 8-16; vinorelbine, 360-480; cisplatin, 240-400; oxaliplatin, 400-800; abraxane, 1200-1800
Study: NCT02265705
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03850886
Drug: Antidiabetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin or Sulphonylurea
Study: NCT01877421
Drug: 2 mg KSL-W
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01877421
Drug: 4 mg KSL-W
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01877421
Drug: 6 mg KSL-W
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01877421
Drug: 10 mg KSL-W
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01877421
Drug: 20 mg KSL-W
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01877421
Drug: 30 mg KSL-W
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01877421
Drug: 50 mg KSL-W
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01877421
Drug: 75 mg KSL-W
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01877421
Drug: 100 mg KSL-W
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01141296
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill identical to active drug will be given PO once a day for 1 year
Study: NCT00781326
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given in doses matching those of nimodipine.
Study: NCT01030224
Drug: AZD9742
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing single IV infusion doses of AZD9742 given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo). Specific doses will be selected by the safety review committee
Study: NCT01030224
Drug: Placebo to match AZD9742
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV infusion of AZD9742 placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo)
Study: NCT00647231
Drug: HKT-500 Topical Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with Ketoprofen Topical Patch
Study: NCT02647151
Drug: AMINOLEVULINIC ACID HYDROCHLORIDE
Normalized name: Aminolevulinic Acid Hydrochloride
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is an intrapatient randomized clinical trial. All patients participating in the trial will receive both, experimental and control treatment, randomization will be used to determine side (right or left for treatment). Three visits will be scheduled. In the first visit epidemiological data will be collected , Actinic Keratoses are counted and drawn in a transparent template and also a photograph of each side. In that first visit treatment the PDT will be also performed, the degree of fluorescence, the pain and the degree of immediate local reaction will be measured.~skin after PDT. In the second visit, to be held at 2 or 3 days, the delayed local reaction degree will be assessed. And in the third visit, held a month of PDT the clinical response and patient satisfaction will be assessed.
Study: NCT00793910
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (sugar pill) taken by mouth thrice daily for 7 days
Study: NCT02308202
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01491243
Drug: Standard treatment with saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. 1 ml/kg/h saline infusion for 48 h in case of abnormal NGAL findings
Study: NCT01525082
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine by mouth twice daily on Days 1 to 14
Study: NCT01702233
Drug: Traumeel S inj
Normalized name: Traumeel S Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traumeel S inj. 2 ml. subacromial 3 times at days 1, 8 and 15
Study: NCT01702233
Drug: Saline inj
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline inj. 2 ml. subacromial 3 times at days 1, 8 and 15
Study: NCT01564225
Drug: EDI200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1 will be dosed at 3 mg/kg/dose. Cohort 2 will be dosed at 10 mg/kg/dose. Both cohorts will receive 2 doses/week for a total of 5 doses.
Study: NCT00799812
Drug: CHG 2% w/v & IPA 70% v/v, swabstick (3 @ once).
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 swabsticks topically applied at the same time to intact skin
Study: NCT00799812
Drug: CHG 2% w/v & IPA 70% v/v swab applied sequentially
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine gluconate 2% w/v and isopropyl alcohol 70% v/v; 3 swabsticks applied sequentially to intact skin.
Study: NCT00799812
Drug: Aqueous CHG 4% w/v applied according to mfr's directions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine gluconate 4% w/v in an aqueous base applied according to mfr's directions. Step 1) 5 ml of Hibiclens applied to a sterile gauze pad. Step 2) Product applied to treatment area on intact skin for 2 minutes. Area dried with sterile towel or sterile gauze. Steps 1 and 2 repeated.
Study: NCT00004317
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: See arm descriptions
Study: NCT00338026
Drug: ECO-4601
Normalized name: Eco-Gard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous IV infusion for 14 days with 7 days recovery (21 day cycle)
Study: NCT00374777
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01224496
Drug: Chinese herbal concoction twice a day for 6 months
Approvals — FDA: no, EMA: no, PMDA: no
Description: Definition of each TCM syndrome is based on TCM theory. Formulation composition is based on each defined TCM syndrome with addition or removal of herbs as indicated by the patient's manifestation
Study: NCT01390246
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Bupropion SR placebo tablet
Study: NCT00871559
Drug: REGN421(SAR153192)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01485952
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily administration (immediate release capsule)
Study: NCT02279641
Drug: RDEA3170 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02510157
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo controlled intervention
Study: NCT00930358
Drug: general anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaesthetic intravenous route
Study: NCT02422030
Drug: Lipitor Tab. 40mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02367313
Drug: Vapendavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vapendavir 264 mg twice daily
Study: NCT02367313
Drug: Vapendavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vapendavir 528 mg twice daily
Study: NCT02367313
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily
Study: NCT00718718
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be adminstered subcutaneously as per the appropriate randomized arm.
Study: NCT00718718
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stable dose of methotrexate will be maintained through Week 24.
Study: NCT01085175
Drug: LMI 1195
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus intravenous injection of LMI 1195
Study: NCT04231435
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral
Study: NCT01886794
Drug: Postmenopausal, topical vaginal estrogen cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vaginal estrogen cream is commonly but not universally used to improve the health of vaginal tissue prior to surgery. This study will provide data regarding estrogen effects for post-menopausal women undergoing pelvic organ prolapse.
Study: NCT01886794
Drug: Placebo Comparator: Postmenopausal, topical placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postmenopausal participants randomized to topical vaginal placebo for about one month's use prior to scheduled surgery.
Study: NCT00927927
Drug: NNC0142-0002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1